Skip to main content
Important Update Actualización importante:

Good news! All CHIP, STAR, and STAR Kids Member Handbooks are now available online. Quick, easy access to your benefits and coverage information - any time!

¡Buenas noticias! Todos los manuales para miembros de CHIP, STAR y STAR Kids ya están disponibles en línea. Obtén acceso rápido y sencillo a la información sobre tus beneficios y cobertura, ¡en cualquier momento!

Change in Preferred Drug List Status for Stimulants and Related Agents Drug Class

Date: August 12, 2025

Attention: All Providers

Effective dates: August 11 and 18, 2025

Call to action: Texas Children’s Health Plan (TCHP) would like to inform providers that effective August 11 and 18, 2025, the Texas Health and Human Services Commission (HHSC) removed the non-preferred status from generic methylphenidate patch products and certain methylphenidate products on the preferred drug list (PDL).

This change is in response to:

  • A reported shortage of the active ingredient in Daytrana patch products, as reported by the manufacturer, Noven, and,
  • Ongoing drug shortages of various brand and generic methylphenidate products.
Impacted MedicationType of ChangeEffective Date
METHYLPHENIDATE 10 MG/9HR PTCHGeneric now preferredAugust 11, 2025
METHYLPHENIDATE 15 MG/9HR PTCHGeneric now preferredAugust 11, 2025
METHYLPHENIDATE 20 MG/9HR PTCHGeneric now preferredAugust 11, 2025
METHYLPHENIDATE 30 MG/9HR PTCHGeneric now preferredAugust 11, 2025
COTEMPLA XR-ODT 8.6 MG TABLETBrand now preferredAugust 18, 2025
COTEMPLA XR-ODT 17.3 MG TABLETBrand now preferredAugust 18, 2025
COTEMPLA XR-ODT 25.9 MG TABLETBrand now preferredAugust 18, 2025
QUILLICHEW ER 20 MG CHEW TABBrand now preferredAugust 18, 2025
QUILLICHEW ER 30 MG CHEW TABBrand now preferredAugust 18, 2025
QUILLICHEW ER 40 MG CHEW TABGeneric now preferredAugust 18, 2025
METHYLPHENIDATE ER 10 MG TABGeneric now preferredAugust 18, 2025
METHYLPHENIDATE ER 20 MG TABGeneric now preferredAugust 18, 2025

How this impacts providers: The change will allow providers to prescribe the generic without requiring PDL prior authorization at this time and continue accessing necessary medication for their patients.

Next step for providers: Prescribers are encouraged to proactively obtain a prescription for the preferred alternatives to avoid disruption in patient’s therapy. Prescribers should share this communication with their staff.

If you have any questions, please email TCHP Pharmacy at: tchppharmacy@texaschildrens.org

For access to all provider alerts,log into: www.texaschildrenshealthplan.org/provideralerts.